Search

Your search keyword '"Dybkaer K"' showing total 141 results

Search Constraints

Start Over You searched for: Author "Dybkaer K" Remove constraint Author: "Dybkaer K" Database MEDLINE Remove constraint Database: MEDLINE
141 results on '"Dybkaer K"'

Search Results

1. A systematic literature review on clonal evolution events preceding relapse in multiple myeloma.

2. DNA mismatch repair defect and intratumor heterogeneous deficiency differently impact immune responses in diffuse large B-cell lymphoma.

3. CRISPR-Cas9 Knockout Screens Identify DNA Damage Response Pathways and BTK as Essential for Cisplatin Response in Diffuse Large B-Cell Lymphoma.

4. Tumor-Infiltrating Normal B Cells Revealed by Immunoglobulin Repertoire Clonotype Analysis Are Highly Prognostic and Crucial for Antitumor Immune Responses in DLBCL.

5. Resistance to vincristine in DLBCL by disruption of p53-induced cell cycle arrest and apoptosis mediated by KIF18B and USP28.

6. An Aggressive Course of Transformed Splenic Diffuse Red Pulp Small B-Cell Lymphoma With Novel Somatic Loss-of-Function Mutation in RB1 .

7. Predictive biomarkers in radioresistant rectal cancer: A systematic review.

8. EBV-positive DLBCL frequently harbors somatic mutations associated with clonal hematopoiesis of indeterminate potential.

9. Feasibility and early clinical impact of precision medicine for late-stage cancer patients in a regional public academic hospital.

10. Early diagnosis of ovarian cancer based on methylation profiles in peripheral blood cell-free DNA: a systematic review.

11. Hsp90 inhibition sensitizes DLBCL cells to cisplatin.

12. Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma.

13. Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial.

14. Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms.

15. Direct costs of antineoplastic and supportive treatment for progressive multiple myeloma in a tax-based health system.

16. Genomic complexity is associated with epigenetic regulator mutations and poor prognosis in diffuse large B-cell lymphoma.

17. The mutational profile of immune surveillance genes in diagnostic and refractory/relapsed DLBCLs.

18. Optimization of Preanalytical Variables for cfDNA Processing and Detection of ctDNA in Archival Plasma Samples.

19. Dynamic Intracellular Metabolic Cell Signaling Profiles During Ag-Dependent B-Cell Differentiation.

20. A bendamustine resistance gene signature in diffuse large B-cell lymphoma and multiple myeloma.

21. Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents.

22. Long Non-Coding RNAs in Diffuse Large B-Cell Lymphoma.

23. DNA methylation biomarkers in peripheral blood of patients with head and neck squamous cell carcinomas. A systematic review.

24. XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53.

25. Identification of BLNK and BTK as mediators of rituximab-induced programmed cell death by CRISPR screens in GCB-subtype diffuse large B-cell lymphoma.

26. A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL.

27. Mutational landscape of immune surveillance genes in diffuse large B-cell lymphoma.

28. Implementing the FAIR Data Principles in precision oncology: review of supporting initiatives.

29. Normal myeloid progenitor cell subset-associated gene signatures for acute myeloid leukaemia subtyping with prognostic impact.

30. MicroRNAs associated to single drug components of R-CHOP identifies diffuse large B-cell lymphoma patients with poor outcome and adds prognostic value to the international prognostic index.

31. Development of a Precision Medicine Workflow in Hematological Cancers, Aalborg University Hospital, Denmark.

32. Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies.

33. High-Throughput Sequencing-Based Investigation of Viruses in Human Cancers by Multienrichment Approach.

34. Aspects of vincristine-induced neuropathy in hematologic malignancies: a systematic review.

35. PD-1/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consortium Program.

36. MicroRNA-155 controls vincristine sensitivity and predicts superior clinical outcome in diffuse large B-cell lymphoma.

37. Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL.

38. Expression of NOTCH3 exon 16 differentiates Diffuse Large B-cell Lymphoma into molecular subtypes and is associated with prognosis.

39. High CXCR4 expression impairs rituximab response and the prognosis of R-CHOP-treated diffuse large B-cell lymphoma patients.

40. A multiple myeloma classification system that associates normal B-cell subset phenotypes with prognosis.

41. A B-cell-associated gene signature classification of diffuse large B-cell lymphoma by NanoString technology.

42. Real world data on rituximab maintenance therapy after frontline immunochemotherapy in grade 1-3a follicular lymphoma.

43. Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma.

44. Stringent or nonstringent complete remission and prognosis in acute myeloid leukemia: a Danish population-based study.

45. Subtype assignment of CLL based on B-cell subset associated gene signatures from normal bone marrow - A proof of concept study.

46. Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy.

47. Oral mucosa tissue gene expression profiling before, during, and after radiation therapy for tonsil squamous cell carcinoma.

48. Hepatitis C virus positive diffuse large B-cell lymphomas have distinct molecular features and lack BCL2 translocations.

49. Interactions between SNPs affecting inflammatory response genes are associated with multiple myeloma disease risk and survival.

50. Human papillomavirus infects placental trophoblast and Hofbauer cells, but appears not to play a causal role in miscarriage and preterm labor.

Catalog

Books, media, physical & digital resources